Are Amazon's Subscription Services Delivering Bigger Returns in 2025?
Amazon's subscription services segment generated $11.7 billion in revenues in the first quarter, up 9.3% year over year. It contributed 7.5% to Amazon's total revenues for the quarter. Our model estimate for 2025 subscription services revenues is pegged at approximately $49 billion, indicating year-over-year growth of 10.9%.
Amazon is refining its fulfillment network and regional delivery systems to speed up service. In the first quarter of 2025, Amazon reported record delivery speeds for Prime members, enabled by improved inventory placement.
Amazon remains focused on increasing the value proposition for subscribers. It reiterated its commitment to keeping prices low, improving delivery speed and expanding product variety. Prime Day 2025, scheduled for July 8-11, will play a central role in this strategy. With exclusive deals and early discounts for Prime members, Amazon expects to drive stronger engagement and spending through the event. The company also plans to continue investing in its Prime Video, shopping, and fulfillment network while leveraging AI to retain and attract subscribers.
Alexa+, which is smarter and more interactive, is now being rolled out for free for Prime members. Prime Day events will serve as another major boost, with exclusive access for members. These initiatives are designed to create a stickier subscription ecosystem.
AMZN Faces Stiff Competition in Subscription Services
Amazon's subscription offerings, led by Prime, are facing growing pressure from rivals like Walmart WMT and Apple AAPL.
Walmart's Walmart+ challenges Prime with benefits like free shipping, fuel discounts and same-day grocery delivery from stores. Meanwhile, Apple's Services business, which bundles services like Apple TV+, Apple Music and Apple Arcade, as well as the growing user base of Apple Pay, has helped Apple achieve more than one billion paid subscribers.
While Walmart targets convenience and delivery speed, Apple focuses on entertainment and digital content. Both are expanding rapidly, offering consumers alternative ecosystems, putting pressure on Amazon to keep innovating and differentiating its subscription suite.
AMZN's Share Price Performance, Valuation and Estimates
AMZN shares have gained 0.8% in the year-to-date (YTD) period, underperforming the Zacks Internet – Commerce industry and the Zacks Retail-Wholesale sector's growth of 7.4% and 5.2%, respectively.
AMZN's YTD Price Performance
From a valuation standpoint, AMZN stock is currently trading at a forward 12-month Price/Sales ratio of 3.25X compared with the industry's 2.17X. AMZN has a Value Score of D.
AMZN's Valuation
The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $1.32 per share, which has been revised upward by a penny over the past 30 days, indicating 7.32% year-over-year growth.
Amazon currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apple Inc. (AAPL): Free Stock Analysis Report
Walmart Inc. (WMT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
23 minutes ago
- Globe and Mail
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901. A replay of the call will also be available on the Enovis website later that day. About Enovis Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Availability of Information on the Enovis Website Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares at Contact:
Globe and Mail
24 minutes ago
- Globe and Mail
Pega to Announce Financial Results for the Second Quarter of 2025 and Host Conference Call and Webcast
Pegasystems Inc. (NASDAQ: PEGA), The Enterprise Transformation Company™, today announced it will report financial results for the second quarter of 2025 on Tuesday, July 22, 2025, after market close. A conference call and audio-only webcast will be conducted at 8:00 a.m. EDT on Wednesday, July 23, 2025. Members of the public and investors are invited to join the call and participate in the question and answer session by dialing 1 (800) 715-9871 (domestic) or 1 (646) 307-1963 (international) and using Conference ID 7346894, or via by logging onto at least five minutes prior to the event's broadcast and clicking on the webcast icon in the Investors section. A replay of the call will also be available on by clicking the Q2/FY'25 Earnings Call link in the Investors section. About Pegasystems Pega is The Enterprise Transformation Company™ that helps organizations Build for Change® with enterprise AI decisioning and workflow automation. Many of the world's most influential businesses rely on our platform to solve their most pressing challenges, from personalizing engagement to automating service to streamlining operations. Since 1983, we've built our scalable and flexible architecture to help enterprises meet today's customer demands while continuously transforming for tomorrow. For more information on Pega (NASDAQ: PEGA), visit
Globe and Mail
24 minutes ago
- Globe and Mail
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the 'Vertex Pharmaceuticals Second Quarter 2025 Earnings Call.' The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X.
